マイクロRNA-210の小分子阻害は,腫瘍性低毒性回路を再プログラムする
Matthew G Costales1, Christopher L Haga1, Sai Pradeep Velagapudi1
1Department of Chemistry, ‡Department of Molecular Therapeutics, and §Department of Neuroscience, The Scripps Research Institute , 130 Scripps Way, Jupiter, Florida 33458, United States.
Journal of the American Chemical Society
|February 28, 2017
まとめ
新しい小分子であるTargapremir-210は,マイクロRNA-210 (miR-210) の前駆者を選択的に標的にします. これは癌細胞の増殖を抑制し,特に低酸素の三重陰性乳がんではアポトーシスを引き起こす.
科学分野:
- 分子生物学
- 癌 研究
- RNAセラピー
背景:
- 低酸素は癌の転移や侵入に 極めて重要です
- マイクロRNA-210 (miR-210) は低酸素誘導因子 (HIF) を調節し,がんの進行に影響を与える.
- ターゲティングRNAは癌治療の新たな境界線を提示しますが,RNAと小分子間の相互作用を研究する方法は限られています.
研究 の 目的:
- miR-210の小分子阻害剤を特定し,特徴づけること
- 小さな分子の作用メカニズムと細胞の選択性を調査する.
- 低酸素三重陰性乳がんに対する 小分子治療の可能性を評価する.
主な方法:
- 小分子とRNAの相互作用を研究するために,化学的クロスリンクとプルダウンによる分離 (Chem- CLIP) が使用された.
- 小分子タルガプレミア-210は,miR-210前駆体ヘアピンと結合するように設計された.
- 低酸素三重陰性乳がんのインビトロおよびインビボモデルを使用した.
主要な成果:
- タルガプレミア-210は選択的にmiR-210前駆体と結合し,成熟したmiR-210の生成を抑制する.
- これは,GPD1Lの減圧,HIF- 1αの減少,そして低酸素状態での癌細胞のアポトーシスにつながる.
- タルガプレミア-210は,マウスの異種移植モデルで腫瘍の成長を抑制する効果を示した.
- Chem- CLIPは,タルガプレミア-210が,発現レベルに基づいて選択的にRNAを認識する能力を明らかにした.
結論:
- 小さな分子は特定のRNAを 選択的に標的として設計され 治療上の利点をもたらします
- タルガプレミア-210は,低酸素性三重陰性乳がんに対する有望な治療戦略です.
- この研究は,トランスクリプトーム内の薬効性RNA標的を特定するための新しいルールを定義しています.
関連する概念動画
MicroRNAs
4.2K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.2K
MicroRNAs
24.4K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.4K
Adaptive Mechanisms in Cancer Cells
7.2K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K
mTOR Signaling and Cancer Progression
5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.0K
Cancer Therapies
10.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.5K
Experimental RNAi
8.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
8.1K


